MIRO
- Miromatrix Medical Inc.
()
Overview
Company Summary
Miromatrix Medical Inc. (MIRO) is a biotechnology company specializing in the development and commercialization of bioengineered organs. The company is leveraging its proprietary perfusion decellularization technology to create functional organs that can be used for transplantation, addressing the critical shortage of donated organs worldwide.
MIRO's perfusion decellularization technology allows for the removal of cells from donor organs while preserving the structure and extracellular matrix, which act as a framework for cell regrowth. This process enables the company to repopulate the decellularized organ with patient-specific cells, creating transplant-ready organs that are less likely to be rejected by the recipient's immune system.
The company's primary focus is on developing bioengineered kidneys and livers. By engineering these complex organs, MIRO aims to address the increasing demand for transplants, reduce wait times, and improve patient outcomes. Additionally, their technology has the potential to minimize the need for immunosuppressive drugs, which can have adverse side effects for transplant recipients.
MIRO is also involved in preclinical and clinical development activities to further advance its bioengineered organ technologies. The company collaborates with academic institutions, research organizations, and pharmaceutical companies to conduct research and development and explore potential commercial partnerships.
Overall, MIRO's pioneering work in the field of bioengineered organs has the potential to revolutionize the transplantation industry by providing a sustainable and effective solution to the shortage of human organs for transplantation.